All In Biotech

NDA 212950 · Viiv Hlthcare

Rukobia

Fostemsavir Tromethamine · Oral

NovelBreakthrough therapyPriority review

Last checked: Nov 19, 2026Latest source record: Feb 13, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jul 2, 2020

Approved uses

2

Original approval plus efficacy supplements

Registered trials

0

0 Phase 3, 0 recruiting

FAERS reports

243

77 serious, 19 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 13, 2024.

RUKOBIA, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations [see Clinical Studies ( 14 )]. RUKOBIA, a human immunodeficiency virus type 1 (HIV-1) gp120-directed attachment inhibitor, in combination with other antiretroviral(s), is indicated for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. ( 1 , 12.4 )

Mechanism: RUKOBIA is an HIV-1 antiretroviral agent [see Microbiology ( 12.4 )].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 24, 2022 Supplement 2 · Efficacy
  • Jul 2, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyLabelLetterReview
1 products under this application
  • RUKOBIA · FOSTEMSAVIR TROMETHAMINE EQ 600MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Fostemsavir Tromethamine" as an intervention, any sponsor and status, largest first.

All 0 trials

No registered drug trials name this ingredient.

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use30
  • nausea17
  • death16
  • product dose omission issue15
  • drug ineffective14
  • viral load increased12
  • rash11
  • dizziness10
  • fatigue10
  • pathogen resistance10
  • product residue present9
  • virologic failure9

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202010
202128
202246
202352
202438
202546
202623

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rukobia (Fostemsavir Tromethamine)

2024 spending

$115M

Beneficiaries

1,505

12,716 claims

Per beneficiary

$76,437

$147.93 per unit

View as table
YearSpending
2020$6,695,198
2021$38,947,235
2022$63,858,997
2023$91,208,742
2024$115,037,191

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.